Strongbridge Biopharma plc (SBBP) — Financial statements
Income statement, balance sheet, and cash flow for Strongbridge Biopharma plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 31↑41.5% | 22↑20.4% | 18↑155.8% | 7 | 0.00 | |
| Cost of Revenue | 2↓42.1% | 4↓4.1% | 4↑168.8% | 1 | 0.00 | |
| Gross Profit | 29↑59.4% | 18↑27.4% | 14↑152.4% | 6 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 26↓16.5% | 31↑21.5% | 25↑47.3% | 17↓13.8% | 20 | |
| General & Administrative Expenses | 41↓10.8% | 46↓27.7% | 63↑74.5% | 36↑144.0% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 41↓10.8% | 46↓27.7% | 63↑74.5% | 36↑144.0% | 15 | |
| Other Expenses | 5↑0.0% | 5↓30.1% | 7↑43.1% | 5 | 0.00 | |
| Operating Expenses | 72↓12.3% | 82↓14.8% | 96↑63.8% | 59↑67.9% | 35 | |
| Total Costs & Expenses | 74↓13.6% | 86↓14.4% | 100↑66.4% | 60↑72.1% | 35 | |
| Operating Results | ||||||
| Operating Income | -43↑32.4% | -64↑22.1% | -82↓54.5% | -53↓51.9% | -35 | |
| Depreciation & Amortization | 5↑0.2% | 5↓29.5% | 7↑43.7% | 5↑50220.0% | 0.01 | |
| EBITDA | -39↑9.2% | -43↓181.7% | 52↑150.9% | -102↓99.9% | -51 | |
| EBIT | -44 | 0.00↓100.0% | 45↑141.8% | -107↓109.2% | -51 | |
| Interest & Other Income | ||||||
| Net Interest Income | -1 | 0.00↑100.0% | -13↓190.2% | -4↓22600.0% | -0.02 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | |
| Interest Expense | 1 | 0.00↓100.0% | 13↑190.2% | 4↑21465.0% | 0.02 | |
| Non-Operating Income | 0.59 | 0.00↑100.0% | -127↓333.2% | 54↑230.8% | 16 | |
| Other Income / Expenses | -2↓111.9% | 16↓85.9% | 114↑294.8% | -59↓256.6% | -16 | |
| Income Before Tax | -45↑5.4% | -48↓247.2% | 32↑129.0% | -112↓117.5% | -51 | |
| Income Tax Expense | -0.02↓100.8% | 2↑229.9% | 0.54↓69.7% | 2↑167.1% | -3 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -45↑8.8% | -49↓255.3% | 32↑128.1% | -113↓133.5% | -49 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -45↑8.8% | -49↓255.3% | 32↑128.1% | -113↓133.5% | -49 | |
| Bottom-Line Net Income | -45↑8.8% | -49↓255.3% | 32↑128.1% | -113↓133.5% | -49 | |
| EPS (Basic) | -0.80↑10.1% | -0.89↓239.1% | 0.64↑120.6% | -3.11↓37.6% | -2.26 | |
| EPS (Diluted) | -0.80↑10.1% | -0.89↓239.1% | 0.64↑120.6% | -3.11↓38.8% | -2.24 | |
| Weighted Average Shares | 56↑1.3% | 55↑11.4% | 50↑36.1% | 37↑69.6% | 22 | |
| Weighted Average Diluted Shares | 56↑1.3% | 55↑11.4% | 50↑36.1% | 37↑68.8% | 22 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.